List of Publications
June 27, 2021
Cadegiani FA, McCoy J, Gustavo Wambier C, Vaño-Galván S, Shapiro J, Tosti A, Zimerman RA, Goren A. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021 Feb 22;13(2):e13492. doi: 10.7759/cureus.13492. PMID: 33633920; PMCID: PMC7899267.
Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus. 2021 Feb 1;13(2):e13047. doi: 10.7759/cureus.13047. PMID: 33643746; PMCID: PMC7885746.
Anderson T, Wideman L, Cadegiani FA, Kater CE. Effects of Overtraining Status on the Cortisol Awakening Response-Endocrine and Metabolic Responses on Overtraining Syndrome (EROS-CAR). Int J Sports Physiol Perform. 2021 Mar 3:1-9. doi: 10.1123/ijspp.2020-0205. Epub ahead of print. PMID: 33662935.
Cadegiani F, Lin EM, Goren A, Wambier CG. Potential risk for developing severe COVID-19 disease among anabolic steroid users. BMJ Case Rep. 2021 Feb 26;14(2):e241572. doi: 10.1136/bcr-2021-241572. PMID: 33637513; PMCID: PMC7919571.
Cadegiani FA, Lim RK, Goren A, McCoy J, Situm M, Kovacevic M, Vañó Galván S, Sinclair R, Tosti A, Wambier CG. Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):e101-e104. doi: 10.1111/jdv.17004. Epub 2020 Nov 8. PMID: 33089570.
Goren A, Cadegiani FA, Wambier CG, Vano-Galvan S, Tosti A, Shapiro J, Mesinkovska NA, Ramos PM, Sinclair R, Lupi O, Hercogova J, McCoy J. Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 Jan;146:110439. doi: 10.1016/j.mehy.2020.110439. Epub 2020 Nov 28. PMID: 33308937; PMCID: PMC7695567.
Cadegiani FA, Silva PHL, Abrao TCP, Kater CE. Novel Markers of Recovery From Overtraining Syndrome: The EROS-LONGITUDINAL Study. Int J Sports Physiol Perform. 2021 Jan 5:1-10. doi: 10.1123/ijspp.2020-0248. Epub ahead of print. PMID: 33406484.
Cadegiani FA, Zimerman RA, Campello de Souza B, McCoy J, Pereira E Costa RA, Gustavo Wambier C, Goren A. The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. Cureus. 2021 Jan 7;13(1):e12565. doi: 10.7759/cureus.12565. PMID: 33437562; PMCID: PMC7793341.
McCoy J, Cadegiani FA, Wambier CG, Herrera S, Vaño-Galván S, Mesinkovska NA, Ramos PM, Shapiro J, Sinclair R, Tosti A, Goren A. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):e243-e246. doi: 10.1111/jdv.17021. Epub 2020 Nov 22. PMID: 33135263.
Goren A, Wambier CG, Herrera S, McCoy J, Vaño-Galván S, Gioia F, Comeche B, Ron R, Serrano-Villar S, Ramos PM, Cadegiani FA, Kovacevic M, Tosti A, Shapiro J, Sinclair R. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e13-e15. doi: 10.1111/jdv.16953. Epub 2020 Oct 21. PMID: 32977363; PMCID: PMC7536996.
McCoy J, Wambier CG, Herrera S, Vaño-Galván S, Gioia F, Comeche B, Ron R, Serrano-Villar S, Iwasiow RM, Tayeb MA, Cadegiani FA, Mesinkovska NA, Shapiro J, Sinclair R, Goren A. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e15-e17. doi: 10.1111/jdv.16956. Epub 2020 Oct 21. PMID: 32977355; PMCID: PMC7536899.
Zimerman RA, Cadegiani FA, Pereira E Costa RA, Goren A, Campello de Souza B. Stay-At-Home Orders Are Associated With Emergence of Novel SARS-CoV-2 Variants. Cureus. 2021 Mar 11;13(3):e13819. doi: 10.7759/cureus.13819. PMID: 33728228; PMCID: PMC7949745.
Cadegiani FA, Wambier CG, Goren A. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Front Med (Lausanne). 2020 Jul 28;7:453. doi: 10.3389/fmed.2020.00453. PMID: 32850920; PMCID: PMC7399048. (I.F.: 3.113)
Cadegiani FA, Goren A, Wambier CG. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses. 2020 Oct;143:110112. doi: 10.1016/j.mehy.2020.110112. Epub 2020 Jul 16. PMID: 32721806; PMCID: PMC7363620. (I.F.: 1.375)
Wambier CG, Mehta N, Goren A, Cadegiani FA. COVID-19, androgens, and androgenetic alopecia. Derm Rev. 2020;1-8. First published: 23 December 2020/ DOI: https://doi.org/10.1002/der2.50
Cadegiani FA. Repurposing existing drugs for COVID-19: an endocrinology perspective. BMC Endocr Disord. 2020 Sep 29;20(1):149. doi: 10.1186/s12902-020-00626-0. PMID: 32993622; PMCID: PMC7523486.
Cadegiani FA, Kater CE. Eating, Sleep, and Social Patterns as Independent Predictors of Clinical, Metabolic, and Biochemical Behaviors Among Elite Male Athletes: The EROS-PREDICTORS Study. Front Endocrinol (Lausanne). 2020;11:414. Published 2020 Jun 26. doi:10.3389/fendo.2020.00414.
Cadegiani FA. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?. Am J Physiol Endocrinol Metab. 2020;318(5):E587‐E588. doi:10.1152/ajpendo.00136.2020.
Cadegiani FA, da Silva PHL, Abrao TCP, Kater CE. Diagnosis of Overtraining Syndrome: Results of the Endocrine and Metabolic Responses on Overtraining Syndrome Study: EROS-DIAGNOSIS. J Sports Med (Hindawi Publ Corp). 2020;2020:3937819. Published 2020 Apr 22. doi:10.1155/2020/3937819.
Cadegiani FA, Kater CE. Inter-correlations Among Clinical, Metabolic, and Biochemical Parameters and Their Predictive Value in Healthy and Overtrained Male Athletes: The EROS-CORRELATIONS Study. Front Endocrinol (Lausanne). 2019;10:858. Published 2019 Dec 10. doi:10.3389/fendo.2019.00858.
Cadegiani FA, Kater CE. Enhancement of hypothalamic-pituitary activity in male athletes: evidence of a novel hormonal mechanism of physical conditioning. BMC Endoc Dis. 2019 Nov 1;19(1):117. Published 2019 Nov 1. doi:10.1186/s12902-019-0443-7.
Cadegiani FA, Kater CE. Novel causes and consequences of overtraining syndrome: the EROS-DISRUPTORS study. BMC Sports Sci Med Rehabil. 2019 Sep 18;11:21. doi: 10.1186/s13102-019-0132-x.
Cadegiani FA, Kater CE. Basal Hormones and Biochemical Markers as Predictors of Overtraining Syndrome in Male Athletes: The EROS-BASAL Study. J Athl Train. 2019 Aug;54(8):906-914. doi: 10.4085/1062-6050-148-18.
Cadegiani FA, Kater CE. Novel insights of overtraining syndrome discovered from the EROS study. BMJ Open Sport Exerc Med. 2019 Jun 20;5(1):e000542. doi: 10.1136/bmjsem-2019-000542.
Cadegiani FA, Kater CE, Gazola M. Clinical and biochemical characteristics of high-intensity functional training (HIFT) and overtraining syndrome: findings from the EROS study (The EROS-HIFT). J Sports Sci. 2019 Feb 20:1-12. doi: 10.1080/02640414.2018.1555912.
Cadegiani FA, Kater CE. Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: results of the EROS study (EROS-PROFILE). J Sports Sci. 2018 Aug;36(16):1902-1910. doi: 10.1080/02640414.2018.1424498. PMID: 29313445.
Cadegiani FA, Kater CE. Hypothalamic-pituitary-adrenal (HPA) axis functioning in overtraining syndrome: findings from Endocrine and Metabolic Responses on Overtraining Syndrome (EROS) - EROS-HPA axis. Sports Med Open. 2017 Dec 8;3(1):45. DOI: 10.1186/s40798-017-0113-0. PMID: 29222606.
Cadegiani FA, Kater CE. Hormonal responses to a non-exercise stress test in athletes with overtraining syndrome: results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) - EROS-STRESS. J Sci Med Sport. 2018 Jul;21(7):648-653. DOI: 10.1016/j.jsams.2017.10.033. PMID: 29157780.
Cadegiani FA, Kater CE. Hormonal aspects of overtraining syndrome: a systematic review. BMC Sports Sci Med Rehabil. 2017 Aug 2;9:14. DOI: https://doi.org/10.1186/s13102-017-0079-8 PMID: 28785411.
Cadegiani FA, Kater CE. Adrenal Fatigue does not exist: a Systematic Review. BMC Endoc Dis. 2016 Aug. DOI: 10.1186/s12902-016-0128-4. PMID: 27557747.
Cadegiani FA et al. Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. BMC Obes. 2017 Feb 21;4:9. DOI: https://doi.org/10.1186/s40608-017-0147-3
Cadegiani FA et al. Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. Diabetes Metab Syndr Obes. 2016 Dec 7;9:443-446. DOI: 10.2147/DMSO.S123244.
Cadegiani FA. Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment. Am J Case Rep. 2016; Jan. 17:51-51.
Cadegiani F, Abrao TPC, da Silva PLH, Kater CE. The “Normal” Hormonal Levels in Athletes: Should Reference Ranges Be Adapted for the Physically Active Population?. J Endocr Soc. 2020;4(Suppl 1):MON-LB305. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2321.
Cadegiani F, da Silva PLH, Abrao TPC, Kater CE. Novel Hormonal and Metabolic Markers of Recovery From Overtraining Syndrome Unveiled by the Longitudinal ARM of the Eros Study - the Eros-Longitudinal Study. J Endocr Soc. 2020;4(Suppl 1):SAT-LB4. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2337.
Cadegiani F, da Silva PLH. Novel Paradoxical Markers of Weight Loss: Is the Worse Actually the Better? a Retrospectiv eanalysis of 1,567 Patients with Obesity With Successful Clinical Weight-Loss Approaches. J Endocr Soc. 2020;4(Suppl 1):MON-LB100. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2338.
Cadegiani FA, da Silva PLH. Clinical Guidelines for the Research on the Endocrinology of Physical Activity and Sport. J Endocr Soc. 2020;4(Suppl 1):MON-LB311. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2333.
Cadegiani F. 5-Year Data of an Aggressive Pharmacological Approach to Moderate and Morbid Obesity: Is Prevention of Bariatric Surgery Feasible in the Long Run?. J Endocr Soc. 2020;4(Suppl 1):MON-LB101. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2340
Cadegiani F, da Silva PLH, Abrao TPC, Kater CE. The Testosterone-To-Estradiol Ratio, Rather Than Testosterone or Estradiol Alone, Is a More Precise Marker of Metabolic-Related Outcomes in Males: Insights From a Systematic Review. J Endocr Soc. 2020;4(Suppl 1):SAT-LB8. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2293.
WHY DID WE CHOOSE CUREUS TO PUBLISH SOME OF OUR WORKS?
Some may criticize the fact that we have published a few papers in a journal with expedited review process and publication, assuming that this is something bad. Well, it seems that the criticism comes from who is not actively studying and publishing about COVID-19. The urge that a pandemic require made journals publish papers too fast in the beginning of the pandemic. However, some of these papers were below the average of the quality of the papers usually published in these journals. With this, journals took two steps behind and started to hold the review process.
However, the sense of urgency was only increasing, since COVID-19 was killing at an exponential rate. With this, thousands of the called preprints started to be published. Preprints are papers that haven’t undergone peer review process, which theoretically means that they a sort of “quality stamp” of any published paper.
Well, in practical terms, it means that the readers had to read the preprint more carefully and make their own conclusions about the quality of the article, which would be more like the role of the reviewers and editors. But this bothered several, despite the need of urgent share of information.
Alongside this story, there is another scientific crisis on the reviewers. Reviewers usually take a lot of their time to thoroughly review and evaluate papers without anything in exchange. Basically a volunteer work in the name of science. But many reviewers started to get more and more tired of the lack of recognition (even with websites like Publons, but this is a merely written recognition) and the quality of reviews started to drop dramatically. Trusting in reviewers, many editors accepted and allowed papers to be published without a minimum quality required for that journal.
In addition, it is becoming harder and longer to get reviewers for a manuscript.
In this scenario completely against the scientific production during a period that required an extreme urgency for therapeutical and preventive solutions, the Cureus Journal of Medical Science. A quick but rigorous and fair review process, after which the editor also truly evaluates your work and request changes and clarifications before accepting. Cureus may be one of the responses to the scientific crisis we are facing.
Although many criticized our papers published in Cureus, none was able to present any actual argument to their content. Under this scrutiny, our papers reassure their quality.